Zimmer Biomet (ZBH) signed a definitive agreement to acquire Monogram Technologies (MGRM) for a cash payment of $4.04 per common share, for a total equity value of about $177 million, the companies said Monday.
Shares of Monogram soared 76% as intraday trading volume catapulted to over 13.4 million from a daily average of about 60,000.
Dare Bioscience (DARE) said Monday that interim results from its phase 3 clinical trial showed that its investigational monthly, hormone-free intravaginal contraceptive, Ovaprene, met the company's expectations.
Shares surged 66% as intraday trading volume climbed to more than 63.8 million from a daily average of about 163,000.
Sonnet BioTherapeutics (SONN) shares soared 72% amid heavy trading after the company said it agreed to merge with Rorschach, backed by Atlas Merchant Capital and Paradigm Operations, and will build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.
More than 40.2 million shares of Sonnet traded intraday compared with a daily average of about 2.91 million.
Price: 93.61, Change: -0.19, Percent Change: -0.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。